FARMAKOVİJİLANS DERNEĞİ

 



FARMAKOVİJİLANS NEDİR?

Advers etkilerin ve beşeri tıbbi ürünlere bağlı diğer muhtemel sorunların saptanması, değerlendirilmesi, tanımlanması ve önlenmesi ile ilgili bilimsel çalışmaları kapsar.

Farmakovijilans "günlük klinik uygulamada ilaçların güvenliği ile ilgili klinik verilerin toplanması, ilaç uygulamasında karşılaşılan sorunların takibi, sorumlu nedenlerin saptanması, tanınması, araştırılması, kaydedilmesi, duyurulması ve gerekli önlemlerin alınması" şeklinde tanımlanabilir.

PV İLE İLGİLİ KAVRAMLAR

ADVERS ETKİ BİLDİRİMİ


VİJİLANS DÜNYASINDAN YANSIMALAR

  • MedWatch - The FDA Safety Information and Adverse Event Reporting Program
    Clarithromycin (Biaxin): Drug Safety Communication - Potential Increased Risk of Heart Problems or Death in Patients With Heart Disease
    Devamı>>

  • Drugs that cause kidney damage

    The list of individual drugs that cause kidney damage is so long that it’s hard to collect all of them


    Devamı>>

  • Ten Drugs Make New FDA Watch List

    Ten drugs or drug classes treating everything from obesity to arthritis made the latest watch list of drugs with possible safety issues that was released by the US Food and Drug Administration (FDA) last week.


    Devamı>>

  • ISoP mid-year training course in Bangkok - 25 & 26 May 2017

    Please feel free to forward this announcement to your colleagues as broadly as you can.


    Devamı>>

  • Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review

    Dokümana ulaşmak için lütfen tıklayınız.


    Devamı>>

  • Paxil Isn't Safe for Teens, New Analysis Says

    A controversial clinical trial of the antidepressant Paxil came to the wrong conclusion when it declared the drug safe and effective for treating troubled teenagers, according to a reanalysis of the original data more than a decade later.


    Devamı>>

  • Chronic Use of Proton Pump Inhibitors Increases Heart Risk

    Lara C. Pullen, PhD
    June 10, 2015


    Devamı>>

  • Multiple ER Visits Linked to Risk of Prescription-Drug Overdose Death

    People with four or more ER visits in the past year were 48 times more likely to die of prescription drug overdose compared to those who visited an ER once or not at all, researchers found. With three visits a year, the risk of overdose death from a prescription drug was 17 times greater.


    Devamı>>

  • The placebome: Where genetics and the placebo effect meet

    How will genomics impact the role of the placebo in patient care and clinical research?


    Devamı>>

  • Increased bioavailability of phenylephrine by co-administration of acetaminophen

    European Journal of Clinical Pharmacology
    February 2015, Volume 71, Issue 2, pp 151-158
    Date: 06 Dec 2014


    Devamı>>

  • Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products--Content and Format; Draft Guidance for Industry; Availability

    Devamı>>

  • Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)

    Devamı>>

  • Patient Safety in the EU

    Devamı>>

  • List of medicines under additional monitoring

    Devamı>>

  • Naproxen CV Safety vs Ibuprofen Challenged in WHI Analysis

    ALLAS, TX — Contrary to a lot of observational data and common belief even among clinicians, regular intake of naproxen entails more cardiovascular risk than ibuprofen, according to an analysis of nonsteroidal...


    Devamı>>

  • FDA Launches Big Data 'openFDA' Initiative, Giving Public Easier Access to Safety Information

    The US Food and Drug Administration (FDA) has launched a long-awaited technology initiative intended to free regulatory data that was once difficult to obtain and harder still to make sense of.


    Devamı>>

  • EMA to Allow Biosimilar Applications to Reference Data from Products Approved Outside EU

    The European Medicines Agency has updated its guidance for pharmaceutical companies on biosimilar medicines to reflect the European Commission's confirmation....


    Devamı>>

  • Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter
    Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter
    Devamı>>

  • Off-Label Use & Safety

    There has been a lot of discussion regarding the off-label use of drugs.  This has been a focus of interest for FDA, EMA, MHRA and other health agencies around the world


    Devamı>>

  • Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and Death

    Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and Death


    Devamı>>

  • Macrolide Antibiotics Associated With Infantile Hypertrophic Pyloric Stenosis

    NEW YORK (Reuters Health) - Treating young infants and women who are pregnant or postpartum with macrolide antibiotics may be associated with infantile hypertrophic pyloric stenosis (IHPS), new research from Denmark suggests.


    Devamı>>

  • Severe Skin Reactions Investigated With Valsartan in Japan

    Michael O'Riordan

    KYOTO, Japan — The Japanese Health, Labor, and Welfare Ministry is currently investigating a potential a link between valsartan (Novartis) and skin eruptions that result in sores and blisters, according to the Japan Times [1].

    Devamı>>

  • Pharmacovigilance: Development of a Drug Safety Eplatform for Physicians, Pharmacists and Consumers
    Drugs and Therapy Studies 2013; volume 3:e4 ulaşmak için lütfen tıklayınız.
    Devamı>>

  • MHRA press statement on Ranbaxy : MHRA
    India produces 10% of the world’s medicines. In the UK 23% of UK Marketing Authorisations name an Indian Manufacturer and 38% name an Indian Active Pharmaceutical Ingredient source.
    Devamı>>




İÇERENKÖY MAH. ÜSKÜDAR- İÇERENKÖY YOLU CAD. NO:8 D:12 ATAŞEHİR / İSTANBUL
Tel: 0216 385 93 33